These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 23303839)

  • 1. Comparison of survival rates in patients with metastatic renal cell carcinoma according to treatment era including cytokine and targeted therapy.
    Takagi T; Kondo T; Kennoki T; Iizuka J; Kobayashi H; Hashimoto Y; Tanabe K
    Jpn J Clin Oncol; 2013 Apr; 43(4):439-43. PubMed ID: 23303839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidemiologic trends in renal cell carcinoma in the cytokine and post-cytokine eras: a registry analysis of 28,252 patients.
    Shek D; Tomlinson B; Brown M; Brunson A; Pan CX; Lara PN
    Clin Genitourin Cancer; 2012 Jun; 10(2):93-8. PubMed ID: 22382008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients.
    Naito S; Yamamoto N; Takayama T; Muramoto M; Shinohara N; Nishiyama K; Takahashi A; Maruyama R; Saika T; Hoshi S; Nagao K; Yamamoto S; Sugimura I; Uemura H; Koga S; Takahashi M; Ito F; Ozono S; Terachi T; Naito S; Tomita Y
    Eur Urol; 2010 Feb; 57(2):317-25. PubMed ID: 19136199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trends in Metastatic Kidney Cancer Survival From the Cytokine to the Targeted Therapy Era.
    Macleod LC; Tykodi SS; Holt SK; Wright JL; Lin DW; Tretiakova MS; True LD; Gore JL
    Urology; 2015 Aug; 86(2):262-8. PubMed ID: 26199164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Editorial comment on: prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients.
    Ohlmann CH
    Eur Urol; 2010 Feb; 57(2):325-6. PubMed ID: 19136198
    [No Abstract]   [Full Text] [Related]  

  • 6. Overall survival and good tolerability of long-term use of sorafenib after cytokine treatment: final results of a phase II trial of sorafenib in Japanese patients with metastatic renal cell carcinoma.
    Naito S; Tsukamoto T; Murai M; Fukino K; Akaza H
    BJU Int; 2011 Dec; 108(11):1813-9. PubMed ID: 21481133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Course of size and density of metastatic renal cell carcinoma lesions in the early follow-up of molecular targeted therapy.
    Hittinger M; Staehler M; Schramm N; Ubleis C; Becker C; Reiser M; Berger F
    Urol Oncol; 2012 Sep; 30(5):695-703. PubMed ID: 21865061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognosis of Japanese patients with previously untreated metastatic renal cell carcinoma in the era of molecular-targeted therapy.
    Shinohara N; Obara W; Tatsugami K; Naito S; Kamba T; Takahashi M; Murai S; Abe T; Oba K; Naito S
    Cancer Sci; 2015 May; 106(5):618-26. PubMed ID: 25711777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristics of long-term and short-term survivors of metastatic renal cell carcinoma treated with targeted therapies: results from the International mRCC Database Consortium.
    Fay AP; Xie WL; Lee JL; Harshman LC; Bjarnason GA; Knox JJ; Ernst S; Wood L; Vaishamayan UN; Yuasa T; Tan MH; Rha SY; Donskov F; Agarwal N; Kollmannsberger CK; North SA; Rini BI; Choueiri TK; Heng DY
    Clin Genitourin Cancer; 2015 Apr; 13(2):150-5. PubMed ID: 25458371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stage migration and increasing proportion of favorable-prognosis metastatic renal cell carcinoma patients: implications for clinical trial design and interpretation.
    Patil S; Ishill N; Deluca J; Motzer RJ
    Cancer; 2010 Jan; 116(2):347-54. PubMed ID: 19921736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of metastatic renal cell carcinoma in the era of targeted therapies.
    Webber K; Cooper A; Kleiven H; Yip D; Goldstein D
    Intern Med J; 2011 Aug; 41(8):594-605. PubMed ID: 21627746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The value of cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy.
    You D; Jeong IG; Ahn JH; Lee DH; Lee JL; Hong JH; Ahn H; Kim CS
    J Urol; 2011 Jan; 185(1):54-9. PubMed ID: 21074811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival of patients undergoing cytoreductive surgery for metastatic renal cell carcinoma in the targeted-therapy era.
    Abern MR; Scosyrev E; Tsivian M; Messing EM; Polascik TJ; Dudek AZ
    Anticancer Res; 2014 May; 34(5):2405-11. PubMed ID: 24778051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma.
    Vasselli JR; Yang JC; Linehan WM; White DE; Rosenberg SA; Walther MM
    J Urol; 2001 Jul; 166(1):68-72. PubMed ID: 11435825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of C-reactive protein kinetics on survival of patients with metastatic renal cell carcinoma.
    Saito K; Tatokoro M; Fujii Y; Iimura Y; Koga F; Kawakami S; Kihara K
    Eur Urol; 2009 May; 55(5):1145-53. PubMed ID: 18930583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing improvements in metastatic renal cell carcinoma systemic treatments from the pre-cytokine to the immune checkpoint inhibitor eras: a retrospective analysis of real-world data.
    Ishihara H; Takagi T; Kondo T; Fukuda H; Tachibana H; Yoshida K; Iizuka J; Kobayashi H; Okumi M; Ishida H; Tanabe K
    Jpn J Clin Oncol; 2021 Apr; 51(5):793-801. PubMed ID: 33324983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival among patients with advanced renal cell carcinoma in the pretargeted versus targeted therapy eras.
    Li P; Wong YN; Armstrong K; Haas N; Subedi P; Davis-Cerone M; Doshi JA
    Cancer Med; 2016 Feb; 5(2):169-81. PubMed ID: 26645975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disease-specific survival in de novo metastatic renal cell carcinoma in the cytokine and targeted therapy era.
    Pal SK; Nelson RA; Vogelzang N
    PLoS One; 2013; 8(5):e63341. PubMed ID: 23658823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metastatic renal cancer and patient survival as a criterion of treatment response.
    Stathopoulos GP; Koutantos J; Rigatos SK; Stathopoulos J; Batzios S; Batziou C
    Oncol Rep; 2008 Feb; 19(2):477-81. PubMed ID: 18202797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of cytoreductive nephrectomy in the era of molecular targeted therapy.
    Polcari AJ; Gorbonos A; Milner JE; Flanigan RC
    Int J Urol; 2009 Mar; 16(3):227-33. PubMed ID: 19207114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.